View printer-friendly version
« Back
November 03, 2003 4:49 p.m.
Teva Reports Q3 Net Income of $157 Million, Up 63% Eps of $0.53, Up 47% Q3 Sales of $813 Million, Up 29%

Jerusalem, Israel, November 3, 2003 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today reported net income of $157 million for the third quarter of 2003, up 63%. Fully diluted EPS reached $0.53, up 47%, and net sales for the quarter increased 29% to $813 million.

For the first nine months of 2003, net sales were $2.3 billion, an increase of 34%. Net income and EPS before the one time income recorded in the second quarter of 2003 reached $432 million and $1.52 for the first nine months, an increase of 58% and 49%, respectively, over the comparable period of 2002. Including one-time net income recorded in the second quarter of 2003, net income and fully diluted EPS amounted to $505 million and $1.77 respectively.

"This has been yet another successful quarter, with record sales and net income, resulting from strong performance in our major markets and with our major products including Copaxone®", said Israel Makov, Teva's President and CEO. "These results are complimented by our strongest US pipeline ever, representing brand sales of over $55 billion, as well as our growing pipeline elsewhere. On another front, we are proud to have recently filed applications in North America and Europe for rasagiline, a new and exciting product submitted for the treatment of Parkinson's disease".

North American pharmaceutical sales (including Copaxone®), which accounted for 63% of total pharmaceutical sales, totaled $452 million compared to $354 million in the third quarter of 2002, an increase of 28%. This increase was mainly attributable to sales of 14 new products that were not sold in the comparable quarter of 2002, the most significant being Amox/Clav and the inclusion of sales, for the first time, of Purinethol, which Teva received from GSK as a settlement agreement between the two companies, as well as increased sales of Copaxone®.

Pharmaceutical sales in Europe (including Copaxone®), which accounted for 25% of total pharmaceutical sales, increased 36% in the quarter to $180 million. This was attributable to the increased generic sales, continued growth of Copaxone® and continuing favorable currency trends.

Global in-market sales of Copaxone® this quarter were $180 million, an increase of 25%. U.S. sales increased by 13% over the third quarter of 2002 to $123 million. Copaxone®'s growth rate in prescriptions was again higher than that of the overall U.S. multiple sclerosis (MS) market. Sales outside the U.S., mainly in Europe, increased by 64%, to $57 million.

API sales to third parties were $95 million, an increase of 33% over the comparable 2002 quarter. Sales, including internal sales to Teva's pharmaceutical businesses, totaled $159 million, an increase of 32% from the third quarter of 2002. The overall growth stemmed from sales of new products like Simvastatin and the increased demand for our API products worldwide.

Teva's gross profit margin reached 46.4% for the third quarter of 2003, as compared to 42.9% in the third quarter in 2002. This reflects mainly favorable product mix, new products and operating efficiencies.

Gross R&D spending for the reported quarter grew by 32% over the comparable quarter of 2002, while net R&D (after participations) was 35% higher, reflecting increases in both generic and innovative R&D operations.
Selling, General and Administrative (SG&A) expenses increased 17% representing 15.4% of sales.

Financial expenses amounted this quarter to approximately $1 million, which follow the exceptionally high financial expenses in the second quarter of 2003.

The tax rate for the third quarter was 20%, significantly higher than that of the third quarter of 2002 (16%), resulted primarily from expiration of certain tax benefits relating to Copaxone®.
Cash flow generated from operating activities for the third quarter of 2003 amounted to $138 million as compared with $92 million in the third quarter of 2002 and with the $354 million generated in the whole of 2002.

The Board of Directors, at its meeting on October 31, 2003, declared a cash dividend per ADR for the third quarter of 2003 of NIS 0.33 (approx. 7.3 cents according to the rate of exchange on October 31, 2003). The record date will be November 17th, 2003, and the payment date will be December 2nd, 2003. Tax will be withheld at a rate of 20%.

Conference Call Details
Teva will host a conference call to discuss the Company's third quarter results on Monday, November 3rd, 2003 at 08:30 a.m. ET. The call will be webcast and can be accessed through the Company's website at Following the conclusion of the call, a rebroadcast will be available until November 9th, 2003, midnight ET on the website or by calling 1-(800) 934-4548 in the U.S. or ++1-(402) 220-1175 outside the U.S. No access code is required.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 30 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients. Close to 90% of Teva's sales are in North America and Europe.

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell their own generic products or successfully extend the exclusivity period of their branded products, Teva's ability to rapidly integrate the operations of acquired businesses, the availability of product liability coverage in the current insurance market, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration ("FDA") and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, acceptance and demand for new pharmaceutical products and new therapies, uncertainties regarding market acceptance of innovative products newly launched, currently being sold or in development, the impact of restructuring of clients, reliance on strategic alliances, exposure to product liability claims, dependence on patent and other protections for innovative products, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission ("SEC"). Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.